Understanding the role of alternative macrophage phenotypes in human atherosclerosis.


Journal

Expert review of cardiovascular therapy
ISSN: 1744-8344
Titre abrégé: Expert Rev Cardiovasc Ther
Pays: England
ID NLM: 101182328

Informations de publication

Date de publication:
Sep 2022
Historique:
pubmed: 10 8 2022
medline: 28 9 2022
entrez: 9 8 2022
Statut: ppublish

Résumé

Atherosclerosis-based ischemic heart disease is still the primary cause of death throughout the world. Over the past decades there has been no significant changes in the therapeutic approaches to atherosclerosis, which are mainly based on lipid lowering therapies and management of comorbid conditions such as diabetes and hypertension. The involvement of macrophages in atherosclerosis has been recognized for decades. More recently, a more detailed and sophisticated understanding of their various phenotypes and roles in the atherosclerotic process has been recognized. This new data is revealing how specific subtypes of macrophage-induced inflammation may have distinct effects on atherosclerosis progression and may provide new approaches for treatment, based upon targeting of specific macrophage subtypes. We will comprehensively review the spectrum of macrophage phenotypes and how they contribute to atherosclerotic plaque development and progression. Various signals derived from atherosclerotic lesions drive macrophages into complex subsets with different gene expression profiles, phenotypes, and functions, not all of which are understood. Macrophage phenotypes include those that enhance, heal, and regress the atherosclerotic lesions though various mechanisms. Targeting of specific macrophage phenotypes may provide a promising and novel approach to prevent atherosclerosis progression.

Identifiants

pubmed: 35942866
doi: 10.1080/14779072.2022.2111301
doi:

Substances chimiques

Lipids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

689-705

Auteurs

Kenji Kawai (K)

Department of Cardiovascular Pathology, CVPath Institute, Gaithersburg, MD, USA.

Aimee E Vozenilek (AE)

Department of Cardiovascular Pathology, CVPath Institute, Gaithersburg, MD, USA.

Rika Kawakami (R)

Department of Cardiovascular Pathology, CVPath Institute, Gaithersburg, MD, USA.

Yu Sato (Y)

Department of Cardiovascular Pathology, CVPath Institute, Gaithersburg, MD, USA.

Saikat Kumar B Ghosh (SKB)

Department of Cardiovascular Pathology, CVPath Institute, Gaithersburg, MD, USA.

Renu Virmani (R)

Department of Cardiovascular Pathology, CVPath Institute, Gaithersburg, MD, USA.

Aloke V Finn (AV)

Department of Cardiovascular Pathology, CVPath Institute, Gaithersburg, MD, USA.
University of Maryland, School of Medicine, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH